公开(公告)号：US20150190546A1

公开(公告)日：2015-07-09

申请号：US14616837

申请日：2015-02-09

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Yair REISNER ,  Benjamin DEKEL ,  Smadar EVENTOV-FRIEDMAN ,  Helena KATCHMAN ,  Elias SHEZEN ,  Anna ARONOVICH ,  Dalit TCHORSH-YUTSIS

IPC: A61L27/36 ,  A61L27/54

CPC classification number: A61L27/3604 ,  A61K35/22 ,  A61K35/407 ,  A61K35/54 ,  A61K39/39541 ,  A61K45/06 ,  A61L27/3641 ,  A61L27/54 ,  A61L2430/28 ,  A61K2300/00

Abstract: A method of treating a renal, hepatic or enzyme-deficiency disorder in a subject in need thereof is disclosed. The method is effected by transplanting into the subject tissue derived from a human or porcine, kidney or liver, the kidney or liver being at a selected gestational stage.

Abstract translation: 公开了在有需要的受试者中治疗肾，肝或酶缺乏障碍的方法。 该方法通过移植到源自人或猪，肾或肝，肾或肝处于选定妊娠阶段的受试组织中来实现。

公开(公告)号：US20150104471A1

公开(公告)日：2015-04-16

申请号：US14578550

申请日：2014-12-22

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yair REISNER

IPC: A61K39/00 ,  A61K45/06

CPC classification number: A61K39/001 ,  A61K31/351 ,  A61K35/17 ,  A61K35/26 ,  A61K35/28 ,  A61K45/06 ,  A61K2039/5158

Abstract: The present invention provides a method of treating a disease in a subject in need thereof via non-syngeneic graft administration without or with reduced concomitant graft rejection. The method comprises administering to the subject a therapeutically effective graft being non-syngeneic with the subject, and a dose of tolerogenic cells being non-syngeneic with both the subject and the graft for preventing or reducing graft rejection in the subject, thereby treating the disease in the subject

Abstract translation: 本发明提供了一种在有需要的受试者中通过非同基因移植物给药治疗疾病的方法，而不伴随或伴有伴随的移植排斥反应。 该方法包括向受试者施用与受试者非同基因的治疗有效的移植物，并且一定剂量的耐受性细胞与受试者和移植物不同，用于预防或减少受试者的移植物排斥，从而治疗疾病 在主题

公开(公告)号：US20230383254A1

公开(公告)日：2023-11-30

申请号：US18232437

申请日：2023-08-10

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yair REISNER ,  Noga OR-GEVA ,  Rotem GIDRON BUDOVSKY ,  Esther BACHAR-LUSTIG ,  Assaf LASK ,  Sivan KAGAN

IPC: C12N5/0783 ,  A61K35/17 ,  A61K39/00 ,  C12N5/00

CPC classification number: C12N5/0637 ,  A61K35/17 ,  A61K39/001 ,  C12N5/0087 ,  A61K2035/122

Abstract: A method of generating an isolated population of non graft versus host disease (GvHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) providing a population of at least 70% memory T cells; (b) contacting the population of memory T cells with an antigen or antigens so as to allow enrichment of antigen reactive cells; and (c) culturing the cells resulting from step (b) in the presence of cytokines so as to allow proliferation of cells comprising the Tcm phenotype. Cells generated by the method, pharmaceutical compositions and methods of treatment are also disclosed.

公开(公告)号：US20230321235A1

公开(公告)日：2023-10-12

申请号：US18020441

申请日：2021-08-11

Applicant: Yeda Research and Development Co. Ltd. ,  Ichilov Tech Ltd.

Inventor： Yair REISNER ,  Anat GLOBERSON LEVIN ,  Esther BACHAR-LUSTIG ,  Assaf LASK ,  Bar NATHANSOHN-LEVI ,  Tova WAKS ,  Galit HORN ,  Zelig ESHHAR

IPC: A61P35/00 ,  C12N5/0783 ,  A61K39/00

CPC classification number: A61K39/4611 ,  A61K39/4631 ,  A61P35/00 ,  C12N5/0636 ,  A61K2239/22 ,  C12N2510/00

Abstract: A method of generating a population of genetically modified veto cells is disclosed. The method comprising: (a) providing a population of cells comprising T cells, the T cells comprising at least 40% memory CD8+ T cells; (b) culturing the population of cells comprising T cells with an antigen or antigens under conditions which allow enrichment of tolerance-inducing antigen-specific cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being depleted of graft versus host (GVH) reactivity; and (c) transducing the cells with a polynucleotide encoding a heterologous cell surface receptor comprising a T cell receptor signaling module, thereby generating the population of genetically modified veto cells.

公开(公告)号：US20220265726A1

公开(公告)日：2022-08-25

申请号：US17737052

申请日：2022-05-05

Applicant: Yeda Research and Development Co. Ltd. ,  Board of Regents, The University of Texas System

Inventor： Yair REISNER ,  Aloukick Kumar SINGH

IPC: A61K35/28 ,  A61K35/17 ,  A61P7/00 ,  A61P37/06 ,  A61K45/06

Abstract: A method of treating or preventing a sickle cell disease in a subject in need thereof is disclosed. The method comprising: (a) transplanting immature hematopoietic cells into the subject; and (b) administering to the subject a therapeutically effective amount of an isolated population of non-GVHD inducing anti-third party cells comprising cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and capable of homing to the lymph nodes following transplantation.

公开(公告)号：US20200289582A1

公开(公告)日：2020-09-17

申请号：US16885331

申请日：2020-05-28

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yair REISNER ,  Chava ROSEN ,  Elias SHEZEN ,  Irit MILMAN KRENTSIS

IPC: A61K35/42 ,  A61K45/06 ,  A61K31/015 ,  A61K35/12 ,  A61K35/28 ,  C12N5/071 ,  A61K9/00 ,  A61K31/255 ,  A61K31/675 ,  A61N5/10

Abstract: A method of conditioning a subject in need of transplantation of progenitor cells in suspension of a tissue of interest is disclosed. The method comprising: (a) administering to a subject a therapeutically effective amount of an agent capable of inducing damage to the tissue of interest, wherein the damage results in proliferation of resident stem cells in the tissue; and subsequently (b) subjecting the subject to an agent which ablates the resident stem cells in the tissue. A method of transplanting progenitor cells in suspension of a tissue of interest to a subject in need thereof is also disclosed.

公开(公告)号：US20190338247A1

公开(公告)日：2019-11-07

申请号：US16478477

申请日：2018-01-18

Applicant: Yeda Research And Development Co. Ltd.

Inventor： Yair REISNER ,  Esther BACHAR-LUSTIG ,  Shlomit REICH-ZELIGER

IPC: C12N5/0783 ,  C07K14/725 ,  C12N5/00 ,  A61K35/17 ,  A61P35/04 ,  A61P35/00 ,  A61P35/02 ,  C07K16/32 ,  C07K16/30 ,  C07K16/28

Abstract: An isolated cytotoxic T-lymphocyte (CTL), said CTL being a tolerance inducing cell and substantially depleted of alloreactivity, and wherein said CTL does not comprise a central memory T-lymphocyte (Tcm) phenotype, the CTL being transduced to express a cell surface receptor comprising a T cell receptor signaling module, is disclosed. Methods of generating same and using same are also disclosed.

公开(公告)号：US20160354410A1

公开(公告)日：2016-12-08

申请号：US15242666

申请日：2016-08-22

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yair REISNER ,  Assaf LASK ,  Eran OPHIR ,  Noga OR-GEVA ,  Adva COHEN ,  Ran AFIK ,  Esther BACHAR-LUSTIG ,  Yaki EIDELSTEIN

IPC: A61K35/17 ,  A61K35/28 ,  C12N5/0783 ,  A61K45/06

CPC classification number: A61K35/17 ,  A61K31/517 ,  A61K35/28 ,  A61K39/001 ,  A61K45/06 ,  A61K2035/124 ,  A61K2039/5158 ,  C12N5/0602 ,  C12N5/0636 ,  C12N5/0637 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/2321 ,  A61K2300/00

Abstract: A method of treating a disease in a subject in need thereof is disclosed. The method comprising: (a) transplanting a non-syngeneic cell or tissue graft to the subject; and (b) administering to the subject a therapeutically effective amount of an isolated population of cells comprising non-graft versus host (GVHD) inducing anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance-inducing cells and capable of homing to the lymph nodes following transplantation, and further wherein the cells are either: (i) non-syngeneic with both the subject and the graft; or (ii) non-syngeneic with the graft and syngeneic with the subject, thereby treating the subject.

公开(公告)号：US20230024587A1

公开(公告)日：2023-01-26

申请号：US17735146

申请日：2022-05-03

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yair REISNER ,  Yaki EIDELSTEIN ,  Eran OPHIR ,  Assaf LASK ,  Ran AFIK ,  Noga OR-GEVA ,  Esther BACHAR-LUSTIG

IPC: A61K35/17 ,  A61K39/00 ,  C12N5/0783 ,  A61K35/22 ,  A61K35/26 ,  A61K35/28 ,  A61K35/34 ,  A61K35/36 ,  A61K35/38 ,  A61K35/39 ,  A61K35/407 ,  A61K35/42

Abstract: A method of generating an isolated population of cells comprising anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance-inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) contacting peripheral blood mononuclear cells (PBMC) with a third party antigen or antigens in the presence of IL-21 so as to allow enrichment of antigen reactive cells; and (b) culturing the cells resulting from step (a) in the presence of IL-21, IL-15 and IL-7 in an antigen free environment so as to allow proliferation of cells comprising the central memory T-lymphocyte (Tcm) phenotype.

公开(公告)号：US20220265725A1

公开(公告)日：2022-08-25

申请号：US17736190

申请日：2022-05-04

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yair REISNER ,  Rakefet SIDLIK MUSKATEL ,  Bar NATHANSOHN-LEVI

IPC: A61K35/28 ,  A61K35/17 ,  A61P35/00 ,  C12N5/0783

Abstract: A method of treating or preventing a T cell mediated autoimmune disease in a subject in need thereof is disclosed. The method comprising: (a) transplanting immature hematopoietic cells into the subject; and (b) administering to the subject a therapeutically effective amount of an isolated population of non-GVHD inducing anti-third party cells comprising cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and capable of homing to the lymph nodes following transplantation.